IN2015DN00143A - - Google Patents

Info

Publication number: IN2015DN00143A
Authority: IN; India
Prior art keywords: antibodies; family member; disclosed; cell death; positive cells
Prior art date: 2012-07-09

Application number

Other languages

English (en)

Inventor

DESROCHES Claudine Brigitte Fernande VERMOT

Olivier Frédéric Subiger

Laurence Françoise Jeanne Marie BOURDIN

Original Assignee

Internat Drug Dev Biotech

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-07-09

Filing date

2013-07-09

Publication date

2015-06-12

2013-07-09 Application filed by Internat Drug Dev Biotech filed Critical Internat Drug Dev Biotech

2015-06-12 Publication of IN2015DN00143A publication Critical patent/IN2015DN00143A/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Communicable Diseases (AREA)
Rheumatology (AREA)
Oncology (AREA)
Virology (AREA)
Pain & Pain Management (AREA)
Transplantation (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

IN143DEN2015 2012-07-09 2013-07-09 IN2015DN00143A (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP12305821.6A EP2684896A1 (de)	2012-07-09	2012-07-09	Antikörper gegen die DR5-Familie, bispezifische oder multivalente Antikörper gegen die DR5-Familie und Verfahren zu deren Verwendung
US201261669866P	2012-07-10	2012-07-10
PCT/EP2013/064466 WO2014009358A1 (en)	2012-07-09	2013-07-09	Anti-dr5 family antibodies, bispecific or multivalent anti-dr5 family antibodies and methods of use thereof

Publications (1)

Publication Number	Publication Date
IN2015DN00143A true IN2015DN00143A (de)	2015-06-12

Family

ID=46514282

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IN143DEN2015 IN2015DN00143A (de)	2012-07-09	2013-07-09

Country Status (15)

Country	Link
US (4)	US9611327B2 (de)
EP (3)	EP2684896A1 (de)
JP (1)	JP6457386B2 (de)
CN (1)	CN104619725B (de)
BR (1)	BR112015000449B1 (de)
CA (1)	CA2878790C (de)
DK (1)	DK2877491T3 (de)
ES (1)	ES2727486T3 (de)
IL (2)	IL236651B (de)
IN (1)	IN2015DN00143A (de)
PL (1)	PL2877491T3 (de)
PT (1)	PT2877491T (de)
SG (2)	SG11201500177PA (de)
SI (1)	SI2877491T1 (de)
WO (1)	WO2014009358A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK3247728T3 (da)	2015-01-20	2020-07-13	Igm Biosciences Inc	Tumornekrosefaktor-(tnf)-superfamiliereceptorbindende molekyler og anvendelser deraf
EP3048116A1 (de)	2015-01-23	2016-07-27	International-Drug-Development-Biotech	Anti-dr5-antikörper mit verbesserter apoptosefähigkeit
TWI688572B (zh) *	2015-01-26	2020-03-21	美商宏觀基因股份有限公司	包含dr5-結合結構域的多價分子
EP3112381A1 (de) *	2015-07-01	2017-01-04	FONDAZIONE IRCCS Istituto Nazionale dei Tumori	Bispezifische antikörper zur verwendung in der krebsimmuntherapie
HUE051896T2 (hu)	2015-07-16	2021-03-29	Inhibrx Inc	Multivalens és multispecifikus DR5-kötõ fúziós fehérjék
MX2018006333A (es)	2015-12-01	2018-08-01	Genmab Bv	Anticuerpos anti-receptor de muerte 5 (dr5) y metodos de uso de los mismos.
CN106397594B (zh) *	2016-10-25	2019-06-04	中国药科大学	一种全人源的抗人死亡受体5的激动剂单链抗体及应用
EP3535291A1 (de)	2016-11-01	2019-09-11	Genmab B.V.	Polypeptidvarianten und verwendungen davon
EP3360898A1 (de)	2017-02-14	2018-08-15	Boehringer Ingelheim International GmbH	Bispezifische, an tnf-related apoptosis-inducing ligand receptor 2 und cadherin 17 bindende, bindungsmoleküle zur behandlung von krebs
EA201991879A1 (ru)	2017-02-10	2020-02-03	Генмаб Б.В.	Варианты полипептидов и их применение
KR101926834B1 (ko) *	2017-03-21	2018-12-07	동아에스티 주식회사	항-dr5 항체 및 그의 용도
MA49259A (fr) *	2017-06-07	2020-04-15	Genmab Bv	Anticorps thérapeutiques à base d'hexamères d'igg mutées
EP3743440A1 (de)	2018-01-24	2020-12-02	Genmab B.V.	Polypeptidvarianten und verwendungen davon
WO2019165340A1 (en) *	2018-02-26	2019-08-29	Igm Biosciences, Inc.	Use of a multimeric anti-dr5 binding molecule in combination with a chemotherapeutic agent for treating cancer
MX2020011552A (es)	2018-05-03	2020-11-24	Genmab Bv	Combinaciones de variantes de anticuerpos y usos de las mismas.
WO2020136218A1 (en) *	2018-12-26	2020-07-02	Imcheck Therapeutics Sas	Btn3a binding proteins and uses thereof
EP3966241A1 (de)	2019-05-09	2022-03-16	Genmab B.V.	Dosierungsschemata für eine kombination von anti-dr5-antikörpern zur verwendung in der behandlung von krebs
US20220411529A1 (en)	2019-11-06	2022-12-29	Genmab B.V.	Antibody variant combinations and uses thereof
US20230293680A1 (en)	2020-07-23	2023-09-21	Genmab B.V.	A composition of anti-dr5 antibodies and an immunomodulatory imide drug for use in treating multiple myeloma
JP2025510548A (ja) *	2022-03-02	2025-04-15	ウォルデンバイオサイエンシズ，インコーポレイティド	新規の可溶性ウロキナーゼ型プラスミノーゲン活性化因子受容体（ｓｕＰＡＲ）結合性分子及びその使用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4342566A (en)	1980-02-22	1982-08-03	Scripps Clinic & Research Foundation	Solid phase anti-C3 assay for detection of immune complexes
US4554101A (en)	1981-01-09	1985-11-19	New York Blood Center, Inc.	Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US5202238A (en)	1987-10-27	1993-04-13	Oncogen	Production of chimeric antibodies by homologous recombination
US5204244A (en)	1987-10-27	1993-04-20	Oncogen	Production of chimeric antibodies by homologous recombination
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
US6284236B1 (en)	1995-06-29	2001-09-04	Immunex Corporation	Cytokine that induces apoptosis
AU735200B2 (en)	1996-04-01	2001-07-05	Genentech Inc.	APO-2LI and APO-3 apoptosis polypeptides
DK1012274T4 (da)	1997-01-28	2011-07-25	Human Genome Sciences Inc	Dødsdomæneholdig receptor-4 (DR4: dødsreceptor 4), medlem af TNF-receptorsuperfamilien og som binder til TRAIL (Apo-2L)
US20050233958A1 (en)	1997-03-17	2005-10-20	Human Genome Sciences, Inc.	Death domain containing receptor 5
US6872568B1 (en)	1997-03-17	2005-03-29	Human Genome Sciences, Inc.	Death domain containing receptor 5 antibodies
ES2316182T3 (es) *	1998-01-15	2009-04-01	Genentech, Inc.	Ligando apo-2.
AU2719099A (en)	1998-01-23	1999-08-09	Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw	Multipurpose antibody derivatives
CA2323757C (en)	1998-04-02	2011-08-02	Genentech, Inc.	Antibody variants and fragments thereof
CA2375149A1 (en)	1999-06-09	2000-12-14	Genentech, Inc.	Apo-2l receptor agonist and cpt-11 synergism
US6444640B1 (en)	1999-09-30	2002-09-03	Ludwig Institute For Cancer Research	Compositions of trail and DNA damaging drugs and uses thereof
US7279160B2 (en)	2000-05-02	2007-10-09	The Uab Research Foundation	Combinations of DR5 antibodies and other therapeutic agents
GB0020442D0 (en)	2000-08-18	2000-10-04	Nokia Networks Oy	Data transmission protocol
US20020155109A1 (en)	2001-04-20	2002-10-24	Lynch David H.	Bispecific antibodies that bind TRAIL-R1 and TRAIL-R2
ES2437992T3 (es)	2001-05-25	2014-01-15	Human Genome Sciences, Inc.	Anticuerpos que se unen inmunoespecíficamente a los receptores de TRAIL
PT1409544E (pt)	2001-07-03	2009-09-16	Genentech Inc	Anticorpos de dr4 humanos e suas utilizações
KR20070010046A (ko) *	2004-04-06	2007-01-19	제넨테크, 인크.	Ｄｒ5 항체 및 그의 용도
US7632497B2 (en)	2004-11-10	2009-12-15	Macrogenics, Inc.	Engineering Fc Antibody regions to confer effector function
US20060206947A1 (en)	2005-02-28	2006-09-14	Scallon Bernard J	Heterodimeric protein binding compositions
AU2007226752A1 (en)	2006-03-10	2007-09-20	Macrogenics, Inc.	Identification and engineering of antibodies with variant heavy chains and methods of using same
KR100847010B1 (ko) *	2006-07-05	2008-07-17	아주대학교산학협력단	세포사멸 수용체 5 (ｄｒ5)에 특이적으로 결합하는 항체 및이를 포함하는 암 예방 또는 치료용 조성물
WO2009002947A2 (en)	2007-06-22	2008-12-31	Affymax, Inc.	Compounds and peptides that bind the trail receptor
UA117901C2 (uk) *	2011-07-06	2018-10-25	Ґенмаб Б.В.	Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування

2012
- 2012-07-09 EP EP12305821.6A patent/EP2684896A1/de not_active Withdrawn
2013
- 2013-07-09 IN IN143DEN2015 patent/IN2015DN00143A/en unknown
- 2013-07-09 EP EP19159204.7A patent/EP3575323B1/de active Active
- 2013-07-09 US US14/413,194 patent/US9611327B2/en active Active
- 2013-07-09 SI SI201331443T patent/SI2877491T1/sl unknown
- 2013-07-09 SG SG11201500177PA patent/SG11201500177PA/en unknown
- 2013-07-09 WO PCT/EP2013/064466 patent/WO2014009358A1/en not_active Ceased
- 2013-07-09 EP EP13734785.2A patent/EP2877491B1/de active Active
- 2013-07-09 PL PL13734785T patent/PL2877491T3/pl unknown
- 2013-07-09 DK DK13734785.2T patent/DK2877491T3/da active
- 2013-07-09 PT PT13734785T patent/PT2877491T/pt unknown
- 2013-07-09 JP JP2015520954A patent/JP6457386B2/ja active Active
- 2013-07-09 CN CN201380036952.2A patent/CN104619725B/zh active Active
- 2013-07-09 BR BR112015000449-0A patent/BR112015000449B1/pt active IP Right Grant
- 2013-07-09 SG SG10201700148UA patent/SG10201700148UA/en unknown
- 2013-07-09 ES ES13734785T patent/ES2727486T3/es active Active
- 2013-07-09 CA CA2878790A patent/CA2878790C/en active Active
2015
- 2015-01-11 IL IL23665115A patent/IL236651B/en active IP Right Grant
2017
- 2017-02-17 US US15/436,583 patent/US10647774B2/en active Active
2019
- 2019-09-22 IL IL269527A patent/IL269527B/en unknown
2020
- 2020-04-06 US US16/841,306 patent/US20200332016A1/en not_active Abandoned
2023
- 2023-09-06 US US18/461,910 patent/US20240141057A1/en active Pending

Also Published As

Publication number	Publication date
IL236651A0 (en)	2015-02-26
EP2684896A1 (de)	2014-01-15
CA2878790A1 (en)	2014-01-16
IL269527A (en)	2019-11-28
EP3575323B1 (de)	2024-09-11
PT2877491T (pt)	2019-06-07
PL2877491T3 (pl)	2020-01-31
JP2015527992A (ja)	2015-09-24
JP6457386B2 (ja)	2019-01-23
US10647774B2 (en)	2020-05-12
SG10201700148UA (en)	2017-02-27
EP2877491A1 (de)	2015-06-03
BR112015000449A2 (de)	2017-08-15
CA2878790C (en)	2023-09-26
DK2877491T3 (da)	2019-06-03
BR112015000449B1 (pt)	2022-12-20
EP2877491B1 (de)	2019-02-27
ES2727486T3 (es)	2019-10-16
EP3575323A1 (de)	2019-12-04
US9611327B2 (en)	2017-04-04
US20240141057A1 (en)	2024-05-02
CN104619725A (zh)	2015-05-13
WO2014009358A1 (en)	2014-01-16
CN104619725B (zh)	2019-04-23
SI2877491T1 (sl)	2019-08-30
US20200332016A1 (en)	2020-10-22
US20150139997A1 (en)	2015-05-21
HK1211044A1 (en)	2016-05-13
IL236651B (en)	2019-10-31
SG11201500177PA (en)	2015-03-30
IL269527B (en)	2021-12-01
US20170260281A1 (en)	2017-09-14

Publication	Publication Date	Title
IN2015DN00143A (de)	2015-06-12
IL262833A (en)	2018-12-31	Metabolically enriched cell culture
IL242273B (en)	2018-10-31	Methods and compositions for increasing regulatory t cells + 4cd
GB2515195B (en)	2015-12-16	Improved fuel cell systems and methods
EP3480321B8 (de)	2021-03-10	Massiv parallele einzelzellanalyse
EP3082840A4 (de)	2017-11-22	Verfahren und tests im zusammenhang mit zirkulierenden tumorzellen
EP2970881A4 (de)	2017-01-25	Zusammensetzungen und verfahren zur neuprogrammierung hämatopoietischer stammzelllinien
IL240881A0 (en)	2015-10-29	Expression of the t cell balance gene, preparations, materials and methods for its use
EP3114716A4 (de)	2017-07-26	Batteriezellen und anordnungen
EP3028328A4 (de)	2017-01-04	Elektrosynthetische oder elektroenergiezelle mit gasdiffusionselektrode(n)
EP3083658A4 (de)	2017-07-12	Verfahren und tests im zusammenhang mit zirkulierenden tumorzellen
EP3080855A4 (de)	2017-07-26	Elektrochemische zellen und komponenten davon
EP3147974A4 (de)	2017-08-02	Batterieanordnung und zellenpack
EP3072953A4 (de)	2017-08-02	Zellkulturbehälter und behälter mit einer zellkultur
GB201319966D0 (en)	2013-12-25	Fuel cell assembly and method
EP3046171A4 (de)	2017-05-17	Brennstoffzelle und brennstoffzellenstapel
GB201418271D0 (en)	2014-11-26	Fuel cell and battery
EP3052104A4 (de)	2017-06-14	Behandlung von entzündungen mit llp2a-bisphosphonatkonjugaten und mesenchymalen stammzellen
EP3087193A4 (de)	2017-08-09	Zusammensetzungen und verfahren zur bereitstellung von aktiver telomerase an zellen in vivo
EP2919309A4 (de)	2015-12-30	Dichtungselement für brennstoffzelle und brennstoffzellendichtungskörper damit
GB201306326D0 (en)	2013-05-22	Fuel cells
ZA201505170B (en)	2025-02-26	Tablets with improved acceptance and good storage stability
EP3164127A4 (de)	2017-11-22	Zusammensetzungen und verfahren zur verbesserung von adoptiven zelltherapien
KR101882068B1 (ko)	2018-07-25	연료 전지의 작동
EP2970883B8 (de)	2021-06-23	Verbesserte plazentastammzellen und verwendungen davon